Diabetes Drugs Market 2019-2025| Size, Share, Opportunities and Forecast | Credence Research

Share this news:

The global diabetes drugs market was valued at US$ 49.26 Bn in 2016.

According to the latest report published by Credence Research, Inc. "Diabetes Drugs Market-Growth, Future Prospects, and Competitive Analysis, 2017-2025," the global market for diabetes drugs was valued at US$ 49.26 billion in 2016.

Market Insights
Diabetes mellitus often referred to as diabetes, is one of the 21st century's largest global health extremities. It is a serious prolonged disease that arises either when the pancreas does not secrete enough insulin (a hormone that regulates glucose, or blood sugar), or when the body can not efficiently use the insulin it secretes. Roughly 415 million adults currently have diabetes, according to the International Diabetes Federation, and this pool will rise to 642 million by 2040. There may be an increase in the number of cases in emerging countries due to population growth, unhealthy diets, obesity, aging, and sedentary lifestyle.

Don't miss out on business opportunities in Diabetes Drugs Market

Contact Us For Customization in Type, Application & Region: https://www.credenceresearch.com/inquiry-before-buying/58812

The primary driving force of the global drug market for diabetes is the increasing prevalence of diabetes, both the number of cases and prevalence have gradually increased over the past few decades. The trend in the population growth rate of older people also reveals the powerful influence on the diabetes drugs market. The market is expected mainly to be driven by the large diabetes-affected patient pool, more  R&D in diabetes diagnosis and treatment, minimally or non-invasive products, and improved diagnosis and treatment rates.

Moreover, it is observed that growing middle-class population, changing demographic profiles, increasing numbers of medical insurance consumers, expanding the economy, and increasing per capita GDP are also expected to provide massive opportunities for manufacturers of diabetes drugs worldwide and especially in the Asia Pacific (APAC) region. The global market for diabetes drugs is categorized into insulin, oral hypoglycemic drugs (anti-diabetes drugs), non-insulin-injectable anti-diabetes drugs, and others. All drugs are delivered orally except for exenatide, insulin, liraglutide, and pramlintide.

Geographically, the global diabetes drugs market is being studied for Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa. North America leads the global market in terms of revenue share and it is anticipated that the region will retain its supremacy during the forecast period. However, the Asia Pacific market will significantly challenge North America's dominance due to an increase in the geriatric population and an increased prevalence of diabetes in developing countries such as China and India.

The global market for diabetes drugs is driven primarily by the growing diabetic population around the world. In the following years, Asia Pacific will occupy the larger market share. Furthermore, countries such as China also fast-growing India and Southeast Asia region will open additional opportunities for market penetration to key companies already having a grip in developed regions.

Get Sample (Free) @ https://www.credenceresearch.com/sample-request/58812

ToC:
Chapter 1. Preface
.............
Chapter 2. Executive Summary
...............
Chapter 3. Diabetes Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Diabetes: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography, 2016
3.6. Value Chain Analysis
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
4.1. Overview
4.2. Attractive Investment Proposition, by Type of Therapy, 2016
4.3. Insulin
4.4. Oral Hypoglycemic Drugs (anti-diabetes drugs)
4.5. Non-insulin Injectable Anti-diabetes Drugs
4.6. Others
4.7. Phase III (Market estimations by 2025)
4.7.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
4.7.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
4.7.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
4.7.4. Others
4.8. Tabular Presentation of Phase II (Qualitative Information)
4.9. Tabular Presentation of Phase Phase I (Qualitative Information)

Chapter 5. Global Diabetes Drugs Market, by Geography, 2015 – 2025
.....................
Chapter 6. Company Profiles
6.1.1. AstraZeneca plc
6.1.2. Business Description
6.1.3. Financial Information (Subject to data availability)
6.1.4. Application Portfolio
6.1.5. Key Developments
6.2. Biocon Limited
6.3. Boston Therapeutics, Inc.
6.4. Cadila Healthcare
6.5. Eli Lilly and Company
6.6. GlaxoSmithKline plc
6.7. Johnson & Johnson
6.8. Lupin Limited
6.9. Merck & Co., Inc.
6.10. Novartis International AG
6.11. Pfizer Inc.
6.12. Ranbaxy Laboratories Limited
6.13. Sanofi S.A.
6.14. Takeda Pharmaceutical Company Ltd.
...............................toc continue

Browse the full report Diabetes Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025 at https://www.credenceresearch.com/report/diabetes-drugs-market

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com

Release ID: 497781

CONTACT ISSUER
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
SUBSCRIBE FOR MORE